If you are diagnosed with stage III colon cancer, you will probably receive about six months of treatment with FOLFOX after surgery. Research shows that this treatment regimen helps prevent recurrence for some – but not all – patients with stage III colon cancer.  A clinical trial has been launched to answer two questions about this current standard of care:

1. Will recurrence rates go down if both FOLFOX and celecoxib (a non-steroidal anti-inflammatory drug similar to aspirin) are used for treatment?

2.  Will recurrence rates stay the same and long term side effects decrease if FOLFOX is used for three months?

Read the rest of this entry »

We have learned that we can prevent colon cancer by taking aspirin. However because of the significant side effects such as gastric ulcer, bleeding complications and kidney problems, aspirin is not recommended for the public to prevent colon cancer.

In an effort to prevent colon cancer but avoid the side effects of aspirin, COX-2 inhibitors such as Celebrex® (celecoxib) was developed and tested to see if they could prevent colon cancer without the side effects of aspirin. Unfortunately, we have witnessed that high doses of Celebrex can cause heart attacks which put a significant hold on the development of these drugs as chemopreventative agents. Read the rest of this entry »